Safety Assessment of TTCA Antitubercular Agents

Institut Pasteur Korea is executing a repeated-dose toxicity evaluation study of a thienothiazolocarboxamide (TTCA) anti-tubercular drug candidate, which is a new class of compounds that show inhibitory activity against both tuberculosis cultures and macrophages. The compounds display synergistic as well as additive efficacy effects in vitro when used in combination with bedaquiline. The scope of work includes a pre-clinical toxicity profile for TTCAs, establishment of a NOAEL, and human dose predictions essential to the further development of the compound class. In response to the continued need to develop new antitubercular agents and adopt new treatment regimens for drug-resistant tuberculosis, Institut Pasteur Korea’s project aims to identify a new class of compounds that could advance as a clinical candidate upon successful outcome of toxicity studies.